Sydney Lupkin

The first price negotiations between Medicare and drug companies has been underway since February. What do we know about how it’s going?

Medicaid is required to cover almost all drugs, but Congress specifically excluded those for weight loss. Even so, 16 states now cover Wegovy. Others are considering it, but it could strain budgets.

Drug company reps commonly visit doctors to talk about new medications. A team of economists wanted to know if that helps patients live longer. They found that for cancer patients, the answer is no.

A economic research study shows that oncologists’ prescribing habits change after they’ve been visited by pharmaceutical sales reps — and it also shows the changes do not extend patients’ lives.

Spoiler: There are some decreases this year, too. Here’s an overview of the changing prices and what to make of them.

Spoiler: There are some decreases this year, too. Here’s an overview of the changing prices and what to make of them.

January is when drug makers typically hike their prices. This year, there’s a mixed bag of price increases and a few notable declines, such as on some forms of insulin.

Shortages of drugs ranging from life-saving chemotherapies to basic generics are straining the health care system. Hospitals are adapting to chronic interruptions in the supply of medicines.

Despite at least nine lawsuits against the government, all companies whose drugs are up for Medicare price negotiation will come to the bargaining table.

A Texas judge ruled that the Food and Drug Administration wrongly approved mifepristone in 2000 and accused it of doing a rush job. Here’s what really went down.